153 related articles for article (PubMed ID: 29412345)
21. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.
Vermitsky JP; Edlind TD
Antimicrob Agents Chemother; 2004 Oct; 48(10):3773-81. PubMed ID: 15388433
[TBL] [Abstract][Full Text] [Related]
22. Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.
Ben-Ami R; Zimmerman O; Finn T; Amit S; Novikov A; Wertheimer N; Lurie-Weinberger M; Berman J
mBio; 2016 Aug; 7(4):. PubMed ID: 27486188
[TBL] [Abstract][Full Text] [Related]
23. Expression of Efflux Pumps and Fatty Acid Activator One Genes in Azole Resistant Candida Glabrata Isolated From Immunocompromised Patients.
Farahyar S; Zaini F; Kordbacheh P; Rezaie S; Falahati M; Safara M; Raoofian R; Hatami K; Mohebbi M; Heidari M
Acta Med Iran; 2016 Jul; 54(7):458-64. PubMed ID: 27424018
[TBL] [Abstract][Full Text] [Related]
24. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the multi-drug efflux systems of pathogenic fungi using functional hyperexpression in Saccharomyces cerevisiae.
Niimi M
Nihon Ishinkin Gakkai Zasshi; 2010; 51(2):79-86. PubMed ID: 20467195
[TBL] [Abstract][Full Text] [Related]
26. Milbemycin A4 oxime as a probe of azole transport in Candida glabrata.
Walker B; Izumikawa K; Tsai HF; Bennett JE
FEMS Yeast Res; 2014 Aug; 14(5):755-61. PubMed ID: 24838041
[TBL] [Abstract][Full Text] [Related]
27. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.
Sanglard D; Ischer F; Bille J
Antimicrob Agents Chemother; 2001 Apr; 45(4):1174-83. PubMed ID: 11257032
[TBL] [Abstract][Full Text] [Related]
28. Overcoming the heterologous bias: an in vivo functional analysis of multidrug efflux transporter, CgCdr1p in matched pair clinical isolates of Candida glabrata.
Puri N; Manoharlal R; Sharma M; Sanglard D; Prasad R
Biochem Biophys Res Commun; 2011 Jan; 404(1):357-63. PubMed ID: 21134356
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and Fluconazole Susceptibility Profile of Candida spp. Clinical Isolates in a Brazilian Tertiary Hospital in Minas Gerais, Brazil.
Neves-Junior A; Cartágenes-Pinto AC; Rocha DA; de Sá LF; Junqueira Mde L; Ferreira-Pereira A
An Acad Bras Cienc; 2015 Aug; 87(2 Suppl):1349-59. PubMed ID: 26312420
[TBL] [Abstract][Full Text] [Related]
30. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the antifungal activity of new medicinal plant extracts active on Candida glabrata by the major transporters and regulators of the pleiotropic drug-resistance network in Saccharomyces cerevisiae.
Kolaczkowski M; Kolaczkowska A; Stermitz FR
Microb Drug Resist; 2009 Mar; 15(1):11-7. PubMed ID: 19216644
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Efflux Pump Activity in Old Candida glabrata Cells.
Bhattacharya S; Fries BC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311061
[TBL] [Abstract][Full Text] [Related]
33. Purification and characterization of Cdr1, the drug-efflux pump conferring azole resistance in Candida species.
Pata J; Moreno A; Wiseman B; Magnard S; Lehlali I; Dujardin M; Banerjee A; Högbom M; Boumendjel A; Chaptal V; Prasad R; Falson P
Biochimie; 2024 May; 220():167-178. PubMed ID: 38158037
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the CgPDR1 and CgERG11 genes in azole-resistant Candida glabrata clinical isolates from Slovakia.
Berila N; Borecka S; Dzugasova V; Bojnansky J; Subik J
Int J Antimicrob Agents; 2009 Jun; 33(6):574-8. PubMed ID: 19196495
[TBL] [Abstract][Full Text] [Related]
35. Mutation of the CgPDR16 gene attenuates azole tolerance and biofilm production in pathogenic Candida glabrata.
Culakova H; Dzugasova V; Perzelova J; Gbelska Y; Subik J
Yeast; 2013 Oct; 30(10):403-14. PubMed ID: 23939632
[TBL] [Abstract][Full Text] [Related]
36. Relationships between respiration and susceptibility to azole antifungals in Candida glabrata.
Brun S; Aubry C; Lima O; Filmon R; Bergès T; Chabasse D; Bouchara JP
Antimicrob Agents Chemother; 2003 Mar; 47(3):847-53. PubMed ID: 12604511
[TBL] [Abstract][Full Text] [Related]
37. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
Vermitsky JP; Earhart KD; Smith WL; Homayouni R; Edlind TD; Rogers PD
Mol Microbiol; 2006 Aug; 61(3):704-22. PubMed ID: 16803598
[TBL] [Abstract][Full Text] [Related]
38. Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice.
Ferrari S; Sanguinetti M; De Bernardis F; Torelli R; Posteraro B; Vandeputte P; Sanglard D
Antimicrob Agents Chemother; 2011 May; 55(5):1852-60. PubMed ID: 21321146
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
40. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
